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Abstract
The National Institutes of Health (NIH) Roadmap for Medical Research initiative, funded by the 
NIH Common Fund and offered through the Clinical and Translational Science Award (CTSA) 
program, developed more than 60 unique models for achieving the NIH goal of accelerating 
discoveries toward better public health. The variety of these models enabled participating 
academic centers to experiment with different approaches to fit their research environment.
A central challenge related to the diversity of approaches is the ability to determine the success 
and contribution of each model. This paper describes the effort by the Evaluation Key Function 
Committee to develop and test a methodology for identifying a set of common metrics to assess 
the efficiency of clinical research processes and for pilot testing these processes for collecting and 
analyzing metrics. The project involved more than one-fourth of all CTSAs and resulted in useful 
information regarding the challenges in developing common metrics, the complexity and costs of 
acquiring data for the metrics, and limitations on the utility of the metrics in assessing clinical 
research performance. The results of this process led to the identification of lessons learned and 
recommendations for development and use of common metrics to evaluate the CTSA effort.
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INTRODUCTION
The 2010 Institute Of Medicine (IOM) Report “National Cancer Clinical Trials System for 
the 21st Century: Reinvigorating the National Cancer Institute Cooperative Group 
Program”1 states “… the current structure and processes of the entire clinical trials system 
need to be redesigned to improve value by reducing redundancy and improving the 
effectiveness and efficiency of trials.” Many trials take too long to open, and part of the 
problem is the number of processes involved. For Phase III trials, Dilts, et al.2 report almost 
300 unique processes possibly needed just to activate a trial, so it should not be surprising 
that it takes approximately 600 days from the origin of a trial until initiation. Even when a 
trial is completed, only half of those trials publish within 30 months; the overall publication 
rate for trials is a dismal 68%.3
At the 2012 Clinical and Translational Science Award (CTSA) Evaluation Key Function 
Committee face-to-face meeting, leadership for the National Center for Advancing 
Translational Sciences highlighted major concerns about clinical trials, including high costs; 
failure to start, recruit, and publish; ethics of incomplete studies; and studies that are never 
published. In the IOM report on the CTSA programs,4 the need for common metrics was 
emphasized. The report states that a program-wide evaluation should include metrics 
reflecting the extent to which CTSAs facilitate clinical studies and reduce delays in clinical 
trials. The report recognizes the difficulty in developing and implementing common metrics 
across the CTSA consortium and emphasizes that program accountability cannot be 
achieved without high-level common metrics. There is an inability to assess the ultimate 
goal of the program, which is to improve public health; therefore, there is a need to discover 
indirect ways the CTSAs contribute to research. For example, metrics providing more real-
time assessments of progress in advancing clinical and translational research could 
ultimately improve public health by changing clinical practice.4
Developing common metrics that assess the efficiency of clinical research is essential for 
achieving several CTSA goals. First, common metrics will enable the CTSA institutions to 
establish benchmarks. The use of common metrics across CTSA institutions in a de-
identified manner will allow sites to gauge their status within the consortium. In addition, 
these benchmarks could be valuable reference points for other efforts attempting to assess 
clinical research efficiency, both within and outside the National Institutes of Health (NIH). 
Second, common metrics would enable the CTSAs to undertake systematic process 
improvement efforts and function as a type of “virtual national laboratory”4 for clinical and 
translational science. Finally, common metrics would provide a basis for aggregating results 
across the entire CTSA initiative, providing greater transparency and accountability to 
Congress and the public.
The Common Metrics Workgroup was formed as a subgroup of the CTSA Evaluation Key 
Function Committee, which was comprised of evaluators from all 62 CTSAs. The purposes 
of the workgroup were to (1) generate potential metrics, (2) define and operationalize the 
most promising initial candidate metrics, and (3) assess the feasibility of collecting data for 
the metrics. The purpose of this paper is to describe the pilot study that the Common Metrics 
Workgroup conducted, the lessons learned, and the potential future directions.
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Generation of Metrics
In the spring of 2012, CTSA evaluators and principal investigators (PIs) collaborated on 
identifying potential metrics for clinical research processes and outcomes. Several hundred 
metrics were generated as a result. During the October 2012 face-to-face meeting of CTSA 
evaluators, 15 metrics were identified as being especially promising based on ratings of 
importance and feasibility. Each of the 15 promising metrics actually constitutes a broad 
category of metrics which could be operationalized in a number of ways. These metrics were 
organized into 6 broad categories (Table 1). This initial pilot focused on the top three 
metrics falling into the category of “Clinical Research Processes”—time from institutional 
review board (IRB) submission to approval, studies meeting accrual goals, and time from 
notice of grant award (NOGA) to first accrual.
Definition and Operationalization of Metrics
During a six-month period, the Common Metrics Workgroup examined the top three metrics 
and recognized a need for a more precise definition and operationalization in order for data 
to be collected consistently and accurately across institutions. For example, we took the 
original metric “time from IRB submission to approval” and further defined it as “the 
number of calendar days from the institution’s official IRB proposal receipt date to the 
official date of IRB approval.” In addition, it was necessary to specify protocol inclusion 
and exclusion rules (e.g., only clinical research, only protocols undergoing full IRB review) 
and to collect data essential for conducting a reasonable interpretation of the context for the 
metrics, including descriptive information about the institutional and protocol (e.g., number 
of IRBs and full-time equivalent support staff, pre-submission assistance in preparing the 
IRB, number of resubmissions). Similar specificity was applied to the other two metrics. For 
the metric “studies meeting accrual goals,” it was necessary to define both the targeted 
number of subjects (the goal) and the observed accrual number to determine the difference. 
In addition, it was vital to record key descriptive variables that could influence or distort 
accrual estimates (e.g., type of study, age or gender exclusions, target population). Finally, 
for the metric “time from NOGA to first accrual”, it was essential to precisely define key 
dates and collect descriptive data for the protocol (e.g., type of study, target study 
population) to enable interpretation of results. For all metrics, a time frame was established 
to retrospectively collect the data. Consequently, each of the three metrics in this study 
actually consisted of a separate reporting protocol containing several operationalized 
measures with a set of accompanying descriptive variables.
PILOT PROJECT
Methods
Study Procedures—Some of the measures in our pilot study required changes in the way 
data are collected at the participating institutions; therefore, the support of the CTSA PIs 
was imperative to ensure data were collected correctly.
Thirteen CTSA institutions with members on the Evaluation Leadership Committee and the 
Common Metrics Workgroup agreed to participate in the initial round of pilot testing. 
Additionally, evaluators from four other institutions volunteered (N = 17). While there was 
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an open invitation to institutions to participate in the pilot testing, the number of institutions 
was purposefully limited to minimize the burden across all CTSAs. By initially pilot testing 
the metrics on a small number of institutions, we were able to generate useful information 
about the feasibility of collecting these data and refining the metrics before piloting them on 
a larger number of institutions.
Each institution was asked to submit a prioritized list of the metric(s) they wished to pilot, as 
well as explanations for why they might not want to pilot a specific metric. They were also 
asked to report data on a minimum of 10 protocols that met the inclusion criteria for the 
metric being piloted
Participating institutions and survey respondents were given access to a ROCKET (Research 
Organization, Collaboration, and Knowledge Exchange Toolkit)5 workspace where 
information about the pilot was centrally located. Information included (1) background on 
the project, (2) project contact information, (3) a link to the survey to enter new data on a 
protocol, and (4) the metric definition.
The pilot phase lasted for six weeks. Conference calls were conducted at three weeks to 
solicit feedback on barriers or challenges needing to be addressed. At the end of the pilot 
phase, we conducted another conference call with the pilot institutions to solicit their 
feedback. In addition, each institution was asked to complete a brief survey about the 
feasibility of collecting data on the metric at their institution.
The CTSA Consortium Coordinating Center version of REDCap (Research Electronic Data 
Capture)6 was used to collect data on the metrics, as well as for the survey, to assess the 
feasibility. All data were kept confidential and no institutional identification was or will be 
released.
Description of Participation—Seventeen academic health centers with CTSAs 
participated in the pilot project. Nine institutions volunteered to submit data for the IRB 
metric, with 67 protocols submitted ranging from 1 to 11 per institution. Four institutions 
participated in the “study meeting accrual goals” metric, with 39 protocols submitted 
ranging from 8 to 11 protocols per institution. Seven institutions participated in the “time 
from NOGA to first accrual” metric, with 52 protocols submitted ranging from 2 to 10 per 
institution. Three institutions volunteered to collect data on more than one metric. Two 
institutions submitted data on the IRB metric and “time from NOGA to first accrual” metric. 
One institution submitted data on the “studies meeting accrual goals” metric and the “time 
from NOGA to first accrual” metric.
Results
The results of the pilot study are shown in Tables 2–4. While these results may be of 
substantive interest, it should be noted that the purpose of the pilot study was to test the 
feasibility of the metrics. Because the sample of institutions is very limited, and the results 
are not necessarily representative of all CTSA organizations or institutions, the results 
should be viewed as illustrative and interpreted with caution.
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IRB Duration Metrics—Eight institutions participated in the IRB duration metrics pilot, 
representing 67 studies. This pilot was limited to protocols with full-board reviews and 
excluded expedited reviews. The key IRB metric was IRB duration, which was successfully 
completed for all protocols; the median duration was 59 days with a range of 16–328 days. 
These results are consistent with those of the two previous CTSA-wide IRB studies.
Number of protocol resubmissions gives us insight into how complex a protocol might have 
been, how prepared investigators were, and how thorough they were in preparations. Results 
indicate that 65.7% of the protocols were resubmitted one or more times and 18.2% required 
four or more resubmissions. Ninety-one percent of protocols were answered (59.7% = yes, 
31.3% = no) when asked whether the study was multisite. When asked whether the study 
was regulated by the Food and Drug Administration (FDA), 89.8% of the protocols were 
answered (60% = yes, 30.8% = no, 9.2% = don’t know). All protocols were answered 
(76.1% = no, 23.9% = yes) when asked whether the study involved an investigational new 
drug (IND), which is valuable for identifying drug trials that are critically important in 
CTSA contexts.
Perhaps equally informative as the survey results is which items were not practical for 
system-wide measurement. For example, when asked which institutional resources were 
available to researchers for assistance with preparing IRB protocols prior to submission, the 
vast majority of institutions (87.5%) indicated all three types of services listed—centralized, 
department, and IRB staff—were available. Therefore, either this question does not have 
enough variability or, more likely, respondents made assumptions about such resources 
without having any actual evidence in the protocol record. Alternatively, when asked 
whether the protocol required an investigational device exemption (IDE), every protocol 
contained an answer but only 1.5% needed an IDE, which reduced the potential value of this 
metric. While any number of such explanatory variables may be correlated with the key 
duration metric, and therefore be potentially valuable, it is difficult to know which are 
relevant in any given situation and whether this differs by institution or type of protocol. 
Many of the descriptive variables are not regularly collected across institutions, and to 
require them to be collected would likely pose a considerable burden because data would 
need to be collected either directly from investigators or by simply reading the protocol, 
which is even less reliable.
Study Meeting Accrual Goals Metrics—Four institutions participated in the “studies 
meeting accrual goal” metrics pilot, representing 39 studies with a range of 8–11 protocols 
per institution. Two institutions reported a total of six multisite studies not eligible for the 
pilot. For this analysis, they were eliminated, leaving 33 studies as the denominator. Missing 
data occurred across all four participating institutions.
Access to the requested study-specific information varied by institution. Across all of the 
studies (aggregated across all sites), 90%–100% provided the number of participants 
recruited, whether the recruitment target was met, how many participants were needed to 
analyze the primary research question, and whether there was access to the number of 
participants needed based on the power analysis. Nearly three-fourths could identify the time 
between IRB approval and first participant accrual; those who could not were unable to 
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provide either the IRB approval date or, more commonly, the date of first accrual. 
Approximately half of the studies were unable to ascertain information on the projected 
recruitment time, the difference between planned and actual recruitment time, and first 
accrual date.
Studies selected varied in the number of participants needed, ranging from 6 to 900. Most 
included both sexes, and one-third had age restrictions. Approximately two-thirds were 
adult-only studies, and nearly 80% required full-board approval; less than half were FDA 
regulated, and 13% involved INDs.
Despite only 54% of studies meeting their recruitment target, only 18% reported having a 
problem recruiting; four studies had established minority recruitment targets. Among the 
45% providing information about length of recruitment (2–96 months), seven lasted less 
than projected, while nine lasted longer than projected. Among the 72% providing 
information, accrual start date ranged from 41 to 646 days after IRB approval.
NOGA to First Accrual Metrics—Eight CTSA sites volunteered to pilot the metric 
“time from NOGA to first accrual.” Seven institutions reported data on 41 studies; one 
institution identified no studies meeting criteria. Of the 41 studies reported, 13 studies did 
not officially meet inclusion criteria (either NOGA was before July 1, 2012, or the study had 
not yet accrued at least one participant). These studies were excluded, leaving 28 studies 
from five institutions. The NOGA was available for all 28 studies; however, the date of first 
accrual was available for only 25.
For the 25 studies that met inclusion criteria, and for which the date of first accrual could be 
determined, the median number of days from NOGA to first accrual was 203 with a range of 
25–380 days. Studies with expedited or “other” types of IRB review had longer intervals 
than full IRB review. For nearly all studies, the contextual variables were reported. The most 
common issue noted by the seven institutions that attempted the metric was the amount of 
time necessary to find the first accrual date for the study. Only one institution found all the 
necessary data in a single database and, in most cases, the PI or research coordinator had to 
be contacted to collect the first accrual data element. In addition, doubt on the merit of the 
metric was indicated in the feedback survey because some studies had a deliberate “planned 
nonaccrual period” built into the study timeline that the metric did not take into account.
Feasibility
At the mid-point of the pilot study, the Common Metrics Workgroup met via a conference 
call with 26 representatives from 16 of the 17 institutions to obtain feedback. When the 
study was complete, we also held another conference call with 23 representatives from 16 
institutions. Similar discussions emerged from the two conference calls. Participants were 
surprised by the amount of time required for data collection. In several instances, the 
representatives thought they could access the data from an institutional database only to find 
that they had to access several databases. Even then, they were not always successful at 
obtaining the necessary data. For most institutions, getting data from the IRB was 
significantly easier than retrieving data on participant accrual.
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The survey was conducted after the institutions finished data collection to obtain additional 
information about the feasibility of collecting data on the metrics. The results of the survey 
confirm information obtained during the conference calls. Some data were easy to collect, 
such as the data regarding IRB receipt or type of IRB submission. Other data, such as 
accrual of first participant or meeting accrual goals, were much more difficult to collect. In 
several instances, the institution had to contact the PI of the study to get these data. This was 
met with challenges, such as low response rate, time to follow-up, and inability to verify 
data. Many noted that the context variables, such as whether the study involved rare 
diseases, were harder to collect because many of these data are not tracked.
IRB Duration Metric—The majority of pilot sites were able to report data on the basic 
metric of “IRB duration” when computing IRB receipt date to final IRB approval date. 
Other variables that impacted IRB review time and were deemed feasible to report included: 
type of IRB review (e.g., full committee vs. other), number of resubmissions, and type of 
study (e.g, multisite, FDA regulated, IND).
Study Meeting Accrual Goals Metric—It was time intensive to find studies that met 
the inclusion criteria. Challenges identifying studies to meet the inclusion criteria were 
classified as: (1) not available in a central location (i.e., the IRB) and (2) could not be found 
in electronic data format, requiring manual collection. Three of the four CTSAs collected 
data on 10 or more studies for the pilot. Two of the four CTSAs included studies with 
multisite trials that were excluded from the pilot.
For some sites, it was difficult to obtain data from IRBs, which is where much of the 
necessary data reside. Challenges included the site’s IRB (1) did not electronically collect 
the data elements, therefore the information had to be manually extracted; (2) did not collect 
data elements at all or did not use the same definition as delineated by the pilot; and (3) staff 
was unresponsive, making it difficult to identify time to review and collect data elements.
For some of the data elements, different definitions and data points were used and/or the 
definitions lacked clarity. For example, the pilot defined “study closure” as “studies that are 
closed to recruitment (studies may still be collecting data or conducting analyses).” For one 
site, the trigger that identifies a study as closed is the submission of a study closure or final 
report to the IRB. An example of unclear definitions includes the establishment of “explicit 
minority accrual targets.” Further explanation of “explicit” and “minority” was requested.
NOGA to First Accrual Metric—It is unlikely that all CTSAs would have enough studies 
to meet the criteria unless the time frame was lengthened. Eight sites attempted the metric 
but only five had studies meeting the criteria. CTSAs that had qualifying studies were able 
to complete the data elements necessary to compute the metric. However, identifying the set 
of qualifying studies and grants was difficult and involved multiple steps. Most CTSAs that 
worked on the metric did not think it would be helpful for understanding research efficiency.
Gathering data on the metric often involved manually abstracting data from several 
databases. In addition, there was a lack of consistency about how data were recorded across 
the multiple databases being used. This metric almost always required contacting the PI or 
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research coordinator to obtain the date of first accrual; it is likely too labor intensive for 
most sites to undertake.
RECOMMENDATIONS
Overall, we found that collecting common metrics has significant value but can be very time 
consuming, resource intensive, and challenging. We need to be sensitive to the number of 
metrics developed since a large number can become unfeasible to collect. The approach 
recommended here is to keep national common metric reporting requirements minimal and 
to use feedback from these metrics to encourage CTSAs to more closely evaluate what 
factors might be driving the results at their institutions.
As a rule, two features are of key importance in developing common metrics: burden and 
value. Ideally, to keep common metrics to a minimum, institutions should focus on metrics 
that are very low burden to both the investigators and the CTSA but high value to the 
institution and the CTSA. However, such metrics are not always readily available or 
identifiable.
First, we recommend keeping cross-institutional common metrics to a minimum, prioritizing 
those that are low burden and high value, which will inevitably result in the highest 
compliance. Second, make certain the metrics are clearly defined and standardized. Without 
identical (or near identical) measures, it is difficult to compare across institutions. To arrive 
at a useful set of measures, it is important to work iteratively, utilizing a formative 
evaluation methodology7; pilot the selected metrics, revise based on the formative results, 
pilot again. As a part of this formative evaluation process, the CTSAs should seek feedback 
from those collecting data on the metrics and incorporate changes on a regular basis to 
adjust for system fluctuations. By recognizing that collecting common metrics can quickly 
become labor and resource intensive, it becomes possible to plan for this expense and, at the 
same time, be realistic about what level of effort is reasonable and appropriate. Some 
specific recommendations for each metric are noted below.
IRB Duration Metric
To understand the contributing process factors of IRB completion time, which we define as 
the time from IRB receipt date to final IRB approval date, we recommend that, at a 
minimum, each institution collect three IRB related variables. The first critical metric is type 
of review, which our pilot data indicates can be collected with a bivariate measure consisting 
of full committee review vs. other type of review. Second, it is important that CTSAs track 
number of resubmissions as this is a key factor in overall duration of the IRB process, 
regardless of the administrative speed of an individual institution’s IRB. Third, type of study 
can often predict longer or shorter IRB times. For example, multisite studies can be more 
complex, as can FDA-regulated studies and IND studies. We recommend that, for now, only 
these three standardized metrics be collected for each institution, and that this initial 
formative data be used to determine whether additional local detailed IRB data are needed 
for process analysis.
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The pilot has demonstrated that these recommended metrics are practical and feasible. In 
addition, they would enable basic benchmarking which would help CTSAs identify 
variability that might warrant subsequent localized, detailed IRB process analyses.
Studies Meeting Accrual Goals Metric
As with the other standardized metrics, it is essential that a clearly worded standardized 
definition and operationalization be developed for studies meeting accrual goals so that 
comparisons can be made across CTSA institutions. After these common metrics are 
developed, significant time will be required to develop the systems necessary to accurately 
report data on accrual. For CTSAs with an existing clinical management system, collecting 
these data will be less of a challenge; however, comparative analyses will not be possible 
until the entire network decides on and adopts a common set of metrics.
Results of this pilot study indicate that access to data for the metrics and actual performance 
on metrics is widely variable, even with only four institutions reporting. Establishing 
common metrics would be difficult, but the process raises awareness about different 
institutional practices and how others are performing on particular metrics for internal 
comparison. These formative data are helpful to support informed discussions of best 
practices regarding both selection of metrics and institutional performance.
NOGA to First Accrual Metric
Results of this pilot study suggest that measuring NOGA to first accrual may only be 
feasible for institutions with clinical trials management systems or similar databases that 
include the identified data elements; contacting PIs and research staff is too high a burden 
for the CTSA given the vast number of studies involved. Accordingly, it is recommended 
that all CTSA institutions move toward instituting a clinical trials management system and, 
until then, those without such a system will be limited to capturing a subset of the clinical 
data.
CONCLUSIONS AND NEXT STEPS
This pilot study constituted an initial concerted effort to explore the feasibility of collecting 
common metrics that can be used across the CTSA initiative to monitor key processes and 
outcomes. It built on prior years of discussion of the CTSA Consortium’s Evaluation Key 
Function Committee, which wrote a paper calling for “standardized metrics and cross-
cutting analyses that enable aggregation” as part of a “balanced set of evaluation activities 
and methods.”5 That paper, echoed in the subsequent IOM report,4 recognized the important 
role of metrics while acknowledging they are not, by themselves, sufficient to address the 
evaluation needs of such a complex initiative. Good evaluation metrics typically raise as 
many questions as they answer. It is seldom possible to tell, from metrics alone, what moves 
them over time or why they fluctuate between sites; for that, we need contextual data, 
hypotheses, deliberate interventions, and more controlled evaluations.
But metrics have a critically important signaling value. Even if they don’t tell us what is 
driving them, they tell us where we are and when we are changing direction. Without a set 
of simple common metrics, the system lacks basic feedback. The most recent CTSA request 
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for application, responding to the IOM report, recognizes the critical importance of 
developing such a set of common metrics and calls for efforts like this pilot study.
The general conclusion of this pilot contains both good and bad news. In terms of 
challenges, this study makes it clear that developing common metrics that could be collected 
across multiple institutions is a difficult endeavor; simple concepts can be surprisingly 
difficult to define. For instance, using “IRB receipt date” as the point to start the clock on 
measuring IRB review processes becomes questionable when some institutions provide 
significant pre-submission proposal assistance, while others focus on post-submission 
support. Comparing these two using the same “IRB receipt date” will not provide accurate 
results and is likely to advantage one institution over the other. Additionally, there are 
countless factors both within and across institutions (e.g., study type, research subject, target 
population) that are likely to yield unique portfolios, which will differentially affect how 
metrics perform.
In addition to the numerous definitional issues, there are contextual challenges in developing 
and collecting common metrics. This pilot study demonstrated that different institutional 
processes and legacy data systems make it difficult to assume what is simple for one 
institution to collect will be equally simple for another. One CTSA may have developed a 
legacy clinical management information system linking subject accrual data to IRB 
information. Other institutions may have evolved separate systems requiring considerable 
labor to connect such data. Without re-engineering both the existing research management 
processes and information systems across all participating institutions, it is likely the 
implementation of common metrics will remain a challenge and generate burdens that vary 
by metric and location.
This pilot also demonstrates the considerable good news regarding common metrics. The 
fact that this pilot was completed shows that it is possible, even if only on a small scale, to 
develop and collect several key common metrics across multiple CTSAs. This pilot also 
provides a template for how the CTSAs might operate as a virtual national laboratory for the 
development of other metrics going forward. It shows that two of the three metrics identified 
as the most important can, in fact, be collected consistently. This type of testing made it 
possible to identify a much simpler and less burdensome set of processes for the next round 
of collection of these metrics. The third metric, from NOGA to first accrual, was especially 
difficult to gather because many institutions are still getting information systems in place 
which standardize subject accrual data across multiple independent clinical studies. 
Consequently, in many cases, collecting these data required contacting individual 
investigators; however, that’s not necessarily bad news. Should NIH and the CTSAs decide 
this is a critically important data point—and its high rating in the metric generation process 
suggests that it is—a formal requirement to collect this data would send a powerful message 
to the CTSA institutions (and many others) that data collection processes in this area need to 
be re-engineered. The CTSA initiative can make major impacts on the clinical research 
management enterprise across institutions by taking a bold stance on these metrics.
As evaluators in the context of a clinical and translational research enterprise, we are steeped 
in the tradition of hypothesis testing and experimentation. We are inherently critical of data 
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and quick to raise questions about how it can be interpreted. The instinctive reaction to this 
pilot study is to identify all of the ways the metrics fall short. When a study or institution has 
a longer IRB review time or slower subject accrual, we can immediately generate a long list 
of legitimate reasons why such a discrepancy might make sense. This is a fundamental 
challenge to the development of common metrics. This pilot study reminds us that, even if a 
metric is not perfect, or even if it can be reinterpreted in many different ways depending on 
contextual factors, there is still an important signaling value in collecting the same metric 
consistently over time. Such common metrics can provide an empirical anchor, a starting 
point for raising questions about the factors that might be driving its movement. In this 
sense, metrics and monitoring are a gateway to the type of deeper evaluation that needs to 
follow. Metrics provide the data that raise the important questions (e.g., why this study took 
so long, why this institution has lower accrual rates). Evaluations involve hypothesizing 
potential performance improvements and assessing whether they affect the metrics and, 
perhaps, answering the important questions.
The next steps in the evolution of common metrics can build on the foundation provided 
here. This pilot offers a useful template for how subgroups of CTSAs can, at relatively low 
cost and researcher burden, identify and collect potential common metrics. One obvious next 
phase would be to replicate this template with the other 12 metrics initially identified as high 
in potential, most likely in several independent pilots using subgroups of CTSAs to spread 
the development costs across the system. Another next step would be wider testing of the 
metrics investigated here. At least two of these metrics have been simplified and refined 
based on this pilot and should be ready for wider production. The third metric, date of first 
subject accrual, probably needs some creative thinking, revision, and another smaller pilot. 
Additionally, since the landscape of clinical and translational science is continually 
evolving, we should conduct another round of gathering input from the broader system to 
check on the longer list of potential metrics developed earlier and identify any newer and 
emerging priorities that should be considered for metric development. The great news of this 
pilot study is that it demonstrates that all of this is possible as the CTSAs move toward 
becoming a virtual national laboratory for reengineering the clinical and translational 
research enterprise.
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Table 1
Fifteen Priority Metric Categories
Clinical Research Processes
Time from institutional review board submission to approval
Studies meeting accrual goals
Time from notice of grant award to first accrual
Careers
Career development
Career trajectory
Services
Volume of investigators who used services
Volume of types of services used
Satisfaction and needs assessment
Economic Return Leveraging and return on investment of pilots and KL2 scholars
Collaboration
Researcher collaboration
Institutional collaboration
Products
Number of technology transfer products
Time to publication
Influence of research publication
Time from publication to research synthesis
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Table 2
Institutional Review Board (IRB) Completion Time Data
Item/Field
Respondents,
No. (%)
Comments/Findings
Institutional Data (N = 8)
Was the institution fully accredited by the Association for the 
Accreditation of Human Research Protection Programs (AAHRPP) 
during the duration of this survey?
8 (100) 5 (62.5%) yes
3 (37.5%) no
Please indicate which institutional resources below are generally 
available to researchers for assistance with preparing IRB protocols 
prior to submission to the IRB.
8 (100) 7 (87.5%) centralized
7 (87.5%) department
7 (87.5%) IRB staff
Approximate number of initial protocols submitted during calendar 
year 2012 that required at least one review by the fully convened 
IRB at your institution for which the data are reported.
8 (100) Responses unusable. Field was a text one and 
responses ranged from
“data cannot be obtained by pilot deadline,” to “156 
initially submitted protocols/research projects were 
reviewed by 1 of the 4 full-committee IRB in 2012,” 
to simply “65%.” Should restrict field to a number.
Of the new protocols submitted to the IRB, what percentage was 
submitted electronically in 2012?
6 (75) 1 (12.5%) noted 50%
4 (62.5%) noted 100%
Of the new protocols submitted to the IRB, what percentage was 
submitted using paper in 2012?
6 (75) 4 (62.5%) noted 0
1 (12.5%) noted 100%
How many full-time equivalent support staff are engaged in the 
processing of protocol submissions for IRB review? Such persons 
may be responsible for reviewing and approving research and/or 
making determinations regarding if projects are exempt human 
subjects research or do not constitute research or research involving 
human subjects?
7 (87.5) Ranged from 5 to 14
Number of IRBs at institution for which data are being reported in 
this study, excluding external IRBs
7 (87.5) Ranged from 1 to 5
Estimate % of your new protocols that were reviewed by an 
external IRB in 2012.
8 (100) Responses unusable. Field was a text one and 
responses ranged from “we do not know the exact 
%,” to “unknown, maybe 25%,” to “>5%.” Should 
restrict field to a number.
Protocol Data (N = 67)
Type of IRB review required 66 (98.5) All were full-board review
IRB receipt date 67 (100)
Final IRB approval date 67 (100)
IRB duration 67 (100) Calculated from above two fields
mean = 75.6 days
median = 59 days
range, 16–328 days
Was the protocol reviewed by an external IRB (e.g., commercial, 
central IRB)?
67 (100) 1 (1.5%) yes
66 (98.5%) no
Was any pre-submission assistance provided for this protocol 
before it was submitted to the IRB?
47 (70.1) 47 (100%) no (for respondents)
Were any revisions required by the fully convened IRB to secure 
final approval?
66 (98.5) 51 (77.6%) yes
14 (20.9%) no
How many times was the protocol resubmitted to the IRB prior to 
receiving IRB approval?
44 (65.7) All but one case did not require a revision, so there is 
only 1 (or 1.5%) true missing value
Research phase 67 (100) 33 (49.3%) Phase I – IV
16 (23.9%) other
18 (26.9%) not specified
Is this a protocol on a rare disease? 67 (100) 4 (6%) yes
37 (55.2%) no
26 (38.8%) don’t know
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Item/Field
Respondents,
No. (%)
Comments/Findings
Study population (check all that apply) 67 (100) 54 (80.6%) adult only
11 (16.4%) children
4 (6%) pregnant
0 (0%) prisoners
2 (3%) judgment impaired
2 (3%) social/ethnic
Are there any sex exclusions? 61 (91) 46 (74.6%) no exclusions
1 (1.5%) females excluded
9 (14.9%) males excluded
Are there any age exclusions? 67 (100) 41 (61.2%) yes
10 (14.9%) no
16 (23.9%) don’t know
Is this a multisite study? 67 (100) 40 (59.7%) yes
21 (31.3%) no
6 (9%) don’t know
Is this an FDA-regulated study? 65 (97) 39 (60%) yes
20 (30.8%) no
6 (9.2%) don’t know
Investigational new drug 67 (100) 51 (76.1%) no
16 (23.9%) yes
Investigational device exemption 67 (100) 66 (98.5%) no
1 (1.5%) yes
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Table 3
Study Meeting Accrual Goals Data
Item/Field (N = 39) Respondents,
No. (%)
Comments/Findings
How many participants were recruited for the study? 39 (100) mean = 87
range, 0–585
How many participants were needed to analyze the primary 
research question based on the original grant proposal?
39 (100) mean = 174
range, 6–900
Do you have access to the number of participants needed to 
analyze the primary research question according to the power 
analysis?
35 (90) 15 yes
4 did not respond
How many participants were needed to analyze the primary 
research question based on the power analysis?
10 (26) 10 provided a number
low = 15 participants
high = 1720 participants
Were there explicit minority accrual targets established? 38 (97) Only 4 reported having minority target
How many months were projected for participant recruitment? 23 (59) low = 0 months
high = 96 months
How many months did actual study recruitment take? 38 (97) low = 2 months
high = 96 months
Difference between planned and actual recruitment 18 (45) 7 studies took shorter than projected
4 were same as projected
9 were longer than projected (5–50 months)
Number of days from institutional review board (IRB) approval to 
first participant accrual
72 to IRB approval date
46 to first accrual date
11 (28%) missing IRB approval date
21 (54%) missing first accrual date
low = 41 days
high = 646 days
Did study meet recruitment targets? 39 (100) 21 (54%) met recruitment target
How long was study open for recruitment? 14 (36) <1 year = 2
>2 years = 7
Problems with study recruitment 39 (100) 7 (18%) yes
Research phase 39 (100) 18 (46%) not specified
13 (33%) Phase II
4 (10%) Phase III
Required IRB review type 39 (100) 31 (79%) full board
8 (21%) expedited
Is this a protocol on a rare disease? 39 (100) 5 (13%) yes
Study population (check all that apply) 39 (100) (1 did not mark 
a choice)
24 (62%) adult only
9 (23%) children only
5 (13%) adult and children
Any sex exclusions? 39 (100) 33 (85%) no exclusions
5 (13%) males excluded
Any age exclusions? 39 (100) 27 (69%) yes
10 (26%) don’t know
Is this a multisite study? 39 (100) 24 (62%) yes
9 (23%) no
6 (15%) don’t know
Is this an FDA- regulated study? 39 (100) 15 (39%) yes
19 (49%) no
5 (13%) don’t know
Investigational new drug (IND) or investigational device 
exemption
39 (100) 13 (33%) IND
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Table 4
Notice of Grant Award to First Accrual Data
Item/Field (N = 28) Respondents,
No. (%)
Comments/Findings, No. (%)
Date of notice of grant award (NOGA) 
- date on the official notice of award 
to the institution
28 (100) Earliest NOGA - July 1, 2012
Latest NOGA - June 14, 2013
Are you able to report the date of first 
accrual?
25 (89) 3 (12) no
Reasons included non-responsive principal investigators (PIs), and PIs not involved 
in recruitment.
Days from NOGA to first accrual 
(auto-calculated field)
25 (89) median = 203 days
min = 25
max = 380
Research phase 28 (100) Mode - “other” specifications included “PI did not indicate,” “longitudinal 
observational study,” “behavioral,” and “pilot.”
2 (7) Phase I
0 (0) Phase I/II
4 (14) Phase II
0 (0) Phase II/III
2 (7) Phase III
0 (0) Phase III/IV
0 (0) Phase IV
0 (0) early (for devices)
11 (39) other
9 (32) not specified
Type of institutional review board 
review required
26 (93) 16 (61) full board
8 (32) expedited review
2 (8) no response
Is this a protocol on a rare disease? 28 (100) 0 (0) yes
27 (96) no
1 (4) don’t know
Study population (check all that 
apply)
28 (100) 21 (75) adult
6 (21) children
1 (4) pregnant women
0 (0) prisoners/incarcerated individuals
3 (11) individuals with impaired decision making
0 (0) special social/ethnic groups
Are there any sex exclusions? 26 (93) 21 (82) yes
1 (4) no
2 (7) don’t know
1 (4) no response
Are there any age exclusions? 27 (96) 24 (90) yes
1 (4) no
1 (4) don‘t know
1 (4) no response
Is this a multisite study? 28 (100) 11 (39) yes
16 (57) no
1 (4) don’t know
0 (0) no response
Is this an FDA- regulated study? 28 (100) 3 (10) yes
24 (86) no
1 (4) don’t know
0 (0) no response
Investigational new drug (IND) or 
investigational device exemption 
(IED)
28 (100) 4 (14) yes IND
0 (0) yes IED
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